Manufacturing Speciality versus diversity: the four-way CDMO race in outsourced HPAPI manufacturing Pharmaceutical TechnologyGlobalData's Drugs By Manufacturer Database reveals the top four CDMOs for innovator and biosimilar HPAPI contract manufacturing.Read full story pharminent July 22, 2026 (Last updated: July 27, 2026) Pharmaceutical Technology GlobalData’s Drugs By Manufacturer Database reveals the top four CDMOs for innovator and biosimilar HPAPI contract manufacturing. Read full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: Samsung Biologics: geographic diversification is a sound business decisionNext: Arrowhead hits ‘best-case scenario’ with latest results for fat-lowering drug Related Stories Manufacturing Trump Threatens 100%–200% Tariffs on Imported Generic Drugs pharminent July 22, 2026 Manufacturing Samsung Biologics: geographic diversification is a sound business decision pharminent July 22, 2026 Manufacturing Cellares and Papillon partner for PPL-001 manufacturing automation pharminent July 22, 2026
